Loading…
Amgen Inc. is projected to rise to $468.42 by 2027, a +29% move from its current price of $363.39. AMGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $358.84 | $363.47 | $368.15 | +0.02% |
| Jul 14 | $357.02 | $363.54 | $370.18 | +0.04% |
| Jul 15 | $355.65 | $363.62 | $371.77 | +0.06% |
| Jul 16 | $354.50 | $363.69 | $373.12 | +0.08% |
| Jul 17 | $353.51 | $363.77 | $374.33 | +0.10% |
| Jul 18 | $352.62 | $363.85 | $375.43 | +0.13% |
| Jul 19 | $351.81 | $363.92 | $376.45 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $351.81 | $363.92 | $376.45 | +0.15% |
| Week 2 | $347.42 | $364.45 | $382.33 | +0.29% |
| Week 3 | $344.20 | $364.99 | $387.03 | +0.44% |
| Week 4 | $341.59 | $365.52 | $391.13 | +0.59% |
| Week 5 | $339.37 | $366.05 | $394.84 | +0.73% |
| Week 6 | $337.42 | $366.59 | $398.28 | +0.88% |
| Week 7 | $335.67 | $367.13 | $401.53 | +1.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors.
The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd.
for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. (AMGN) is a healthcare stock currently priced at $374.15 per share. It has a market capitalization of $201.93B and ranks 64 by market cap. This places Amgen among large-cap healthcare peers with a broad portfolio of therapies and ongoing commercial and collaboration activity.
The near-term price picture aligns with a neutral to bullish setup depending on the year, while the longer-term forecast shows meaningful upside potential driven by higher average prices in later years.
A major floor 14.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
Price is pressing into resistance (3.0% away) — a breakout level to watch.
A major ceiling 10.4% above — clearing it would confirm fresh momentum.
Key AMGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $365.91 | Sell | $364.85 | Sell |
| MA 10 | $364.60 | Sell | $362.81 | Buy |
| MA 20 | $356.44 | Buy | $357.52 | Buy |
| MA 50 | $343.61 | Buy | $350.41 | Buy |
| MA 100 | $351.81 | Buy | $346.62 | Buy |
| MA 200 | $337.51 | Buy | $337.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.47 | Neutral |
| Stoch RSI (14) | 33.24 | Neutral |
| CCI (20) | 56.76 | Neutral |
| Williams %R (14) | -36.56 | Info |
| MACD (12,26,9) | 0.54 | Buy |
| ROC (12) | 4.72 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 63.44 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | 16.80 | Buy |
| Ultimate (7,14,28) | 59.84 | Neutral |
| Momentum (10) | 10.57 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 365.75 | Sell |
| ADX (14) | 18.98 | Neutral |
| ATR (14) | 3.91 | Info |
The near-term technical picture points to a bullish tilt, with RSI14 at 70 and the stock trading above its key moving averages. The SMA50 is $341.40 and the SMA200 is $335.34, suggesting the price is leading the medium- to long-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $320.72 | $363.39 | $475.13 | 0% | Neutral | |
| $383.62 | $468.42 | $598.00 | +29% | Bullish | |
| $410.09 | $510.14 | $668.86 | +40% | Bullish | |
| $430.56 | $543.86 | $728.26 | +50% | Bullish | |
| $440.20 | $563.56 | $768.22 | +55% | Bullish | |
| $481.98 | $624.57 | $864.85 | +72% | Bullish | |
| $560.08 | $733.98 | $1,030.81 | +102% | Bullish | |
| $606.77 | $803.54 | $1,143.11 | +121% | Bullish | |
| $665.67 | $890.31 | $1,281.67 | +145% | Bullish | |
| $696.93 | $940.93 | $1,369.63 | +159% | Bullish | |
| $1,020.75 | $1,437.40 | $2,192.60 | +296% | Bullish | |
| $1,664.92 | $2,514.44 | $4,111.36 | +592% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $320.72 | $363.39 | $439.96 | +0.00% |
| August 2026 | $320.49 | $375.20 | $448.79 | +3.25% |
| September 2026 | $314.86 | $370.37 | $446.46 | -1.29% |
| October 2026 | $318.37 | $376.03 | $456.26 | +1.53% |
| November 2026 | $326.19 | $386.60 | $471.67 | +2.81% |
| December 2026 | $325.87 | $387.47 | $475.13 | +0.22% |
Click any year to see its month-by-month AMGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AMGN is projected to trade between $320.72 and $475.13, averaging $363.39 — a potential gain of 0% from today's $363.39. Price action looks broadly range-bound.
Amgen Inc.'s 2027 outlook centres on $468.42, within a $383.62 to $598.00 range. That is up +29% on the projected 2026 average. That marks a +29% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, AMGN could reach as high as $668.86, with a base case around $510.14 and support toward $410.09 — roughly +40% from $363.39. Momentum favours further upside here.
Expect AMGN to range from $430.56 to $728.26 through 2029. The $543.86 average target implies a +50% move from current prices. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The AMGN price prediction for 2030 points to an average of $563.56 (low $440.20, high $768.22) — a potential gain of +55% on today's $363.39. Momentum favours further upside here.
In 2031, AMGN is projected to trade between $481.98 and $864.85, averaging $624.57 — a potential gain of +72% from today's $363.39. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Amgen Inc.'s 2032 outlook centres on $733.98, within a $560.08 to $1,030.81 range. That is up +18% on the projected 2031 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2033, AMGN could reach as high as $1,143.11, with a base case around $803.54 and support toward $606.77 — roughly +121% from $363.39. Buyers look set to stay in control over this stretch.
Expect AMGN to range from $665.67 to $1,281.67 through 2034. The $890.31 average target implies a +145% move from current prices. That is up +11% on the projected 2033 average. Momentum favours further upside here.
The AMGN price prediction for 2035 points to an average of $940.93 (low $696.93, high $1,369.63) — a potential gain of +159% on today's $363.39. Buyers look set to stay in control over this stretch.
In 2040, AMGN is projected to trade between $1,020.75 and $2,192.60, averaging $1,437.40 — a potential gain of +296% from today's $363.39. That is up +53% on the projected 2035 average. Momentum favours further upside here.
Amgen Inc.'s 2050 outlook centres on $2,514.44, within a $1,664.92 to $4,111.36 range. That is up +75% on the projected 2040 average. That marks a +592% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in AMGN today (≈ 2.751864 AMGN) could be worth
$6,919.39
+$5,919.39 (+592%) by 2050 · US Dollar
Based on the average projected AMGN price of $2,514.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMGNwould be worth at today's price.
$1,000 invested in AMGN on Jul 10, 2025 (≈ 3.329227 AMGN) would be worth
$1,209.81
+$209.81 (+21.0%) today · 1.21× · US Dollar
Based on a AMGN entry price of $300.37 vs. today's $363.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $374.15 | $971.24 | -2.9% |
| 1 month ago | $337.73 | $1,075.98 | +7.6% |
| 3 months ago | $351.02 | $1,035.24 | +3.5% |
| 6 months ago | $325.54 | $1,116.27 | +11.6% |
| 1 year ago | $300.37 | $1,209.81 | +21.0% |
| All time (5.0y) ago | $244.83 | $1,484.25 | +48.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMGN forecast.
Our base-case forecast reaches $730.00 around 2032.
Implied market cap at $730.00: $393.99B
The multi-year forecast shows bullish sentiment across the horizon. For 2027 the average price is $491.24 with a min of $402.13 and a max of $627.55, corresponding to an ROI of 31.3%. By 2028 the average price rises to $533.68 (ROI 42.6%), and by 2029 to $567.97 (ROI 51.8%), with 2030 averaging $601.31 (ROI 60.7%).
The forecast continues to be bullish with 2040 averaging $1,567.19 (ROI 318.9%) and 2050 averaging $2,781.29 (ROI 643.4%). Across these years the sentiment remains BULLISH. However, these figures are estimates, not guarantees, and carry inherent uncertainty and volatility (annualized volatility is listed at 30%).
Tap a question to reveal the answer.
Min $320.72, Avg $374.15, Max $491.70. ROI 0%. Sentiment NEUTRAL.
Min $402.13, Avg $491.24, Max $627.55. ROI 31.3%. Sentiment BULLISH.
Yes. The 2027 forecast shows a max of $627.55 and the 2027 average is $491.24, with the 2030 average at $601.31, indicating upside potential beyond $500.
Min $1,112.74, Avg $1,567.19, Max $2,391.02. ROI 318.9%. Sentiment BULLISH.
Min $1,841.35, Avg $2,781.29, Max $4,548.28. ROI 643.4%. Sentiment BULLISH.
Amgen Inc. Community Discussion
0Share your Amgen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.